Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
This target is a long noncoding RNA gene (lncRNA) transcribed in the antisense direction relative to the ADAMTSL1 locus on human chromosome 9[1][6]. It is not a protein-coding gene and does not function as an enzyme, receptor, transporter, or classical therapeutic target. Antisense transcripts such as this often regulate the expression of their sense counterparts (in this case, ADAMTSL1) through mechanisms including chromatin modification, transcriptional interference, RNA masking, and modulation of mRNA stability[2][4]. There is currently no evidence for a direct role of this antisense transcript in disease, drug interaction, safety concerns, or use as a biomarker. Its biological significance is inferred from broader studies of antisense lncRNAs, which are increasingly recognized for their contribution to gene regulatory networks, but detailed functional characterization of ENSG00000304884 is lacking in public databases[1][6].
Not applicable; general mechanisms for antisense transcripts include chromatin remodeling, transcriptional interference, RNA masking, and dsRNA-dependent regulation[2][4] No known drug-specific mechanisms
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Novel transcript, antisense to ADAMTSL1 (ENSG00000304884).